RT @mtmdphd@twitter.com

Outlook for Targeted Protein Degradation - @kdonovan1008@twitter.com @LLSResearch@twitter.com @LLSusa@twitter.com #ASH22 #oncopharm #caxtx

🐦🔗: https://twitter.com/mtmdphd/status/1601218092993953792

RT @mtmdphd
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial [Sun, Dec 11, 2022] Manier et al. Abs 569 #ASH22 https://ash.confex.com/ash/2022/webprogram/Paper159933.html #mmsm #caxtx